About lutetium lu dotatate lu dota tyr octreotate
Radiolabeled somatostatin analog radiopharmaceutical
Used for
- Treats adults with certain advanced, somatostatin-receptor-positive neuroendocrine tumors.
Usual adult dose
7.4 GBq (200 mCi) intravenously every 8 weeks for four doses; specialist-administered.
Common side effects
- Nausea and vomiting
- Low blood cell counts
- Kidney toxicity
- Liver enzyme changes
Important warnings
- Can cause serious bone marrow suppression and infection or bleeding.
- May cause kidney damage; amino-acid infusions are given for protection.
- Can cause fetal harm; effective contraception is needed during treatment and afterward.
- Requires radiation-safety precautions and monitoring by a specialist team.
Pregnancy
Can harm an unborn baby. Avoid during pregnancy; pregnancy status is checked before treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for 2.5 months after the final dose.
Interactions
- Somatostatin analog medicines may affect treatment timing and tumor imaging; the oncology team manages their use.
- Radiation-sensitizing chemotherapy may increase toxicity; concurrent use is generally avoided.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.